When it comes to litigation strategy, drug businesses have another option to consider in some cases thanks to recent rulings from the courts of England and Wales.
For years much of the focus on creating value from intellectual property has been on patents, but the emergence of a group of new technologies may help to rewrite the rules on monetisation. Patents will still play a crucial role but look set to become part of a broader mix of intangible assets in the discussion around value creation.
Brand name pharmaceutical companies are facing a policy-making onslaught; with their IP strategies firmly in the spotlight, many are being forced to speak up for the rights that underpin their products.
Understanding a company’s intellectual property is a crucial part of any investor’s acquisition due diligence as it provides an insight into a target’s overall management and points to a business’s possible future direction.
Large portfolios can often give companies a lot of sway in licensing discussions, but those numbers can be manipulated and skew the true strength of a business’s patent position.
Shanghai was the only place to be in early December as IPBC Asia once again attracted the continent’s leading patent players for three days of discussion and debate, along with plenty of networking.
From uncertainty over patent eligibility to the forces of convergence increasingly shaping the sector, IP strategy has never been more important for medical device companies.
Solar technology is one of the key drivers of the renewable energy market, with a band of leading innovators helping to shape the sector.
IAM’s Asia IP elite is bigger than ever as some of the continent’s largest companies continue to push the envelope on IP value creation. This year we welcome a host of newcomers to the list.
